Royalty Pharma acquired a royalty interest in AstraZeneca's cliramitug.
4 reports, 2 independent
Updated Aug 13
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royalty Pharma acquired a royalty interest in AstraZeneca's cliramitug.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
Royalty Pharma
biopharmaceutical company based in New York City
Related events
- AstraZeneca acquired Fusion Pharmaceuticals for approximately US$2 billion in 2024.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Royalty Pharma outperformed the market so far this year, based on data from August 6, 2025.
- Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.
- AstraZeneca's drug was tested in collaboration with Pfizer's drug.